info@seagull-health.com
SeagullHealth
search
Elglustat(Cerdelga)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Cerdelga(Elglustat) Instructions:Uses,Dosage, Side Effects
CERDELGA® (eliglustat) is an oral capsule medication classified as a glucosylceramide synthase inhibitor. It is specifically designed for the long-term management of Gaucher disease type 1 (GD1) in adults.
Its use is contingent upon the patient's CYP2D6 metabolizer status, which must be determined by an FDA-cleared test prior to prescription, as this status directly dictates the appropriate dosing regimen.
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who have been identified as CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) via an FDA-cleared test. It is not recommended for ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
EMs and IMs: 84 mg twice daily
PMs: 84 mg once daily
Dosage adjustments are required when co-administered with CYP2D6 or CYP3A inhibitors, or in patients with hepatic impairment.
Capsules must be swallowed whole; do not crush, dissolve, or open.
May be taken with or without food.
Avoid grapefruit products.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
